Patent Suits Trigger Molecular Diagnostics Business Uncertainty

Investment in new molecular diagnostics biomarkers, particularly genetic markers, is suffering due to substantial patent law uncertainties, according to test developers at last week's Biotechnology Industry Organization conference in Chicago